<abstract xmlns="http://www.w3.org/1999/xhtml">The <bold>objective</bold> of the current study is to evaluate the complication rates (embolic and hemorrhagic events) in deep venous thrombosis (DVT) patients on different types of oral anticoagulation therapy (OAC): direct oral anticoagulant therapy and vitamin K antagonist therapy.<bold>Methods:</bold> A number of 62 DVT patients were included and divided in two groups, depending on the type of oral anticoagulation therapy administered. The first group was composed of patients treated with direct oral anticoagulant treatment (Dabigatran, Rivaroxaban) and the second group was composed of patients treated with vitamin K antagonist (Acenocumarol). General data, including BMI and comorbidities were noted. Embolic and hemorrhagic events were noticed.<bold>Results</bold>: in the first group of patients (DOAC therapy), a number of 34 patients were included (14 of them with BMI higher than 25 kg/m2 and 14 with concomitant atrial fibrillation), while the second group comprised of 28 patients treated with VKA (21 of them with a high BMI and only 3 of them with atrial fibrillation). After a mean period of 36 months of anticoagulant therapy, complications were present in 17 patients, hematuria (8 episodes) and pulmonary embolism (4 cases) were the most frequent, with no difference regarding the treatment applied.<bold>Conclusion:</bold> No statistically significant difference was encountered regarding embolic and hemorrhagic event rates in our deep vein thrombosis patients.</abstract>

The objective of the current study is to evaluate the complication rates (embolic and hemorrhagic events) in deep venous thrombosis (DVT) patients on different types of oral anticoagulation therapy (OAC): direct oral anticoagulant therapy and vitamin K antagonist therapy.Methods: A number of 62 DVT patients were included and divided in two groups, depending on the type of oral anticoagulation therapy administered. The first group was composed of patients treated with direct oral anticoagulant treatment (Dabigatran, Rivaroxaban) and the second group was composed of patients treated with vitamin K antagonist (Acenocumarol). General data, including BMI and comorbidities were noted. Embolic and hemorrhagic events were noticed.Results: in the first group of patients (DOAC therapy), a number of 34 patients were included (14 of them with BMI higher than 25 kg/m2 and 14 with concomitant atrial fibrillation), while the second group comprised of 28 patients treated with VKA (21 of them with a high BMI and only 3 of them with atrial fibrillation). After a mean period of 36 months of anticoagulant therapy, complications were present in 17 patients, hematuria (8 episodes) and pulmonary embolism (4 cases) were the most frequent, with no difference regarding the treatment applied.Conclusion: No statistically significant difference was encountered regarding embolic and hemorrhagic event rates in our deep vein thrombosis patients.

The Complication Rates of Oral Anticoagulation Therapy in Deep Venous Thrombosis

County Department of Forensic Medicine Ialomita

University of Medicine, Pharmacy, Sciences and Technology of Targu Mures

Acta Marisiensis - Seria Medica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"The Complication Rates of Oral Anticoagulation Therapy in Deep Venous Thrombosis"}

The objective of the current study is to evaluate the complication rates (embolic and hemorrhagic events) in deep venous thrombosis (DVT) patients on different...

The Complication Rates of Oral Anticoagulation Therapy in Deep Venous Thrombosis

Pubblicato online: 26 set 2019

Pagine: 87 - 90

Ricevuto: 12 mag 2019

Accettato: 10 giu 2019

DOI: https://doi.org/10.2478/amma-2019-0012

Parole chiave
deep venous thrombosis, direct oral anticoagulants, Acenocumarol, obesity

© 2019 Ionela Silivastru Cozlea et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The Complication Rates of Oral Anticoagulation Therapy in Deep Venous Thrombosis

Pubblicato online: 26 set 2019

Pagine: 87 - 90

Ricevuto: 12 mag 2019

Accettato: 10 giu 2019

DOI: https://doi.org/10.2478/amma-2019-0012

Parole chiavedeep venous thrombosis, direct oral anticoagulants, Acenocumarol, obesity

© 2019 Ionela Silivastru Cozlea et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
deep venous thrombosis, direct oral anticoagulants, Acenocumarol, obesity